Tomas J. Heyman's Insider Trades & SAST Disclosures
Tomas J. Heyman's most recent trade in Akero Therapeutics Inc was a trade of 26,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 8, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Tomas J. Heyman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2024 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 37,014 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Sale of securities on an exchange or to another person at price $ 54.67 per share. | 16 Jun 2023 | 26,000 | 0 (0%) | 0% | 54.7 | 1,421,529 | Common Stock |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.04 per share. | 16 Jun 2023 | 26,000 | 26,000 (0%) | 0% | 25.0 | 651,040 | Common Stock |
| Xilio Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 53,500 | 53,500 | - | - | Stock Option (Right to Buy) | |
| Invivyd Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Xilio Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 26,400 | 26,400 | - | - | Stock Option (right to buy) | |
| Invivyd Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 14,439 | 14,439 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 28,879 | 28,879 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges